Costimulatory molecules as adjuvants for immunotherapy

James W. Hodge, John W. Greiner, Kwong Yok Tsang, Helen Sabzevari, Chie Kudo-Saito, Douglas W. Grosenbach, James L. Gulley, Philip M. Arlen, John L. Marshall, Dennis Panicali, Jeffrey Schlom

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Tumor-associated antigens (TAAs) are by definition either weakly immunogenic or functionally nonimmunogenic. Therefore, efforts have concentrated on the development of vaccine strategies in which the presentation of TAAs to the immune system results in far greater activation of T cells than that occurring naturally in the host. Several strategies are being explored in our laboratory and others to enhance the immunogenicity of TAAs. These are: (a) placing the gene coding for the tumor antigen, as a transgene, into poxvirus vectors. (b) The use of diversified prime and boost vaccine strategies employing two different types of poxvirus vectors. (c) The use of T-cell costimulation; accomplished by placing transgenes for different T-cell costimulation molecules into viral vectors along with the transgenes for the TAA. (d) Altering the amino acid sequence of the TAA to enhance the host immune response. (e) The use of cytokines, and in particular GM-CSF, as a biologic adjuvant. This review will focus on the current state of the use of costimulatory molecules as adjuvants for immunotherapy, and in particular, as immunomodulators for cancer vaccines.

Original languageEnglish
Pages (from-to)788-803
Number of pages16
JournalFrontiers in Bioscience
Volume11
Issue number1 P.447-888
DOIs
Publication statusPublished - 2006
Externally publishedYes

Fingerprint

Neoplasm Antigens
Immunotherapy
Tumors
T-cells
Antigens
Molecules
Transgenes
Poxviridae
T-Lymphocytes
Vaccines
Cancer Vaccines
Immune system
Immunologic Factors
Granulocyte-Macrophage Colony-Stimulating Factor
Genes
Chemical activation
Amino Acid Sequence
Immune System
Cytokines
Amino Acids

Keywords

  • B7-1
  • Costimulation
  • Fowlpox
  • ICAM-1
  • Immunotherapy
  • LFA-3
  • Review
  • Therapeutics
  • Treatment
  • TRICOM
  • Vaccinia

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Hodge, J. W., Greiner, J. W., Tsang, K. Y., Sabzevari, H., Kudo-Saito, C., Grosenbach, D. W., ... Schlom, J. (2006). Costimulatory molecules as adjuvants for immunotherapy. Frontiers in Bioscience, 11(1 P.447-888), 788-803. https://doi.org/10.2741/1837

Costimulatory molecules as adjuvants for immunotherapy. / Hodge, James W.; Greiner, John W.; Tsang, Kwong Yok; Sabzevari, Helen; Kudo-Saito, Chie; Grosenbach, Douglas W.; Gulley, James L.; Arlen, Philip M.; Marshall, John L.; Panicali, Dennis; Schlom, Jeffrey.

In: Frontiers in Bioscience, Vol. 11, No. 1 P.447-888, 2006, p. 788-803.

Research output: Contribution to journalArticle

Hodge, JW, Greiner, JW, Tsang, KY, Sabzevari, H, Kudo-Saito, C, Grosenbach, DW, Gulley, JL, Arlen, PM, Marshall, JL, Panicali, D & Schlom, J 2006, 'Costimulatory molecules as adjuvants for immunotherapy', Frontiers in Bioscience, vol. 11, no. 1 P.447-888, pp. 788-803. https://doi.org/10.2741/1837
Hodge JW, Greiner JW, Tsang KY, Sabzevari H, Kudo-Saito C, Grosenbach DW et al. Costimulatory molecules as adjuvants for immunotherapy. Frontiers in Bioscience. 2006;11(1 P.447-888):788-803. https://doi.org/10.2741/1837
Hodge, James W. ; Greiner, John W. ; Tsang, Kwong Yok ; Sabzevari, Helen ; Kudo-Saito, Chie ; Grosenbach, Douglas W. ; Gulley, James L. ; Arlen, Philip M. ; Marshall, John L. ; Panicali, Dennis ; Schlom, Jeffrey. / Costimulatory molecules as adjuvants for immunotherapy. In: Frontiers in Bioscience. 2006 ; Vol. 11, No. 1 P.447-888. pp. 788-803.
@article{a201f043cd9143e5990403f8a4f15276,
title = "Costimulatory molecules as adjuvants for immunotherapy",
abstract = "Tumor-associated antigens (TAAs) are by definition either weakly immunogenic or functionally nonimmunogenic. Therefore, efforts have concentrated on the development of vaccine strategies in which the presentation of TAAs to the immune system results in far greater activation of T cells than that occurring naturally in the host. Several strategies are being explored in our laboratory and others to enhance the immunogenicity of TAAs. These are: (a) placing the gene coding for the tumor antigen, as a transgene, into poxvirus vectors. (b) The use of diversified prime and boost vaccine strategies employing two different types of poxvirus vectors. (c) The use of T-cell costimulation; accomplished by placing transgenes for different T-cell costimulation molecules into viral vectors along with the transgenes for the TAA. (d) Altering the amino acid sequence of the TAA to enhance the host immune response. (e) The use of cytokines, and in particular GM-CSF, as a biologic adjuvant. This review will focus on the current state of the use of costimulatory molecules as adjuvants for immunotherapy, and in particular, as immunomodulators for cancer vaccines.",
keywords = "B7-1, Costimulation, Fowlpox, ICAM-1, Immunotherapy, LFA-3, Review, Therapeutics, Treatment, TRICOM, Vaccinia",
author = "Hodge, {James W.} and Greiner, {John W.} and Tsang, {Kwong Yok} and Helen Sabzevari and Chie Kudo-Saito and Grosenbach, {Douglas W.} and Gulley, {James L.} and Arlen, {Philip M.} and Marshall, {John L.} and Dennis Panicali and Jeffrey Schlom",
year = "2006",
doi = "10.2741/1837",
language = "English",
volume = "11",
pages = "788--803",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",
number = "1 P.447-888",

}

TY - JOUR

T1 - Costimulatory molecules as adjuvants for immunotherapy

AU - Hodge, James W.

AU - Greiner, John W.

AU - Tsang, Kwong Yok

AU - Sabzevari, Helen

AU - Kudo-Saito, Chie

AU - Grosenbach, Douglas W.

AU - Gulley, James L.

AU - Arlen, Philip M.

AU - Marshall, John L.

AU - Panicali, Dennis

AU - Schlom, Jeffrey

PY - 2006

Y1 - 2006

N2 - Tumor-associated antigens (TAAs) are by definition either weakly immunogenic or functionally nonimmunogenic. Therefore, efforts have concentrated on the development of vaccine strategies in which the presentation of TAAs to the immune system results in far greater activation of T cells than that occurring naturally in the host. Several strategies are being explored in our laboratory and others to enhance the immunogenicity of TAAs. These are: (a) placing the gene coding for the tumor antigen, as a transgene, into poxvirus vectors. (b) The use of diversified prime and boost vaccine strategies employing two different types of poxvirus vectors. (c) The use of T-cell costimulation; accomplished by placing transgenes for different T-cell costimulation molecules into viral vectors along with the transgenes for the TAA. (d) Altering the amino acid sequence of the TAA to enhance the host immune response. (e) The use of cytokines, and in particular GM-CSF, as a biologic adjuvant. This review will focus on the current state of the use of costimulatory molecules as adjuvants for immunotherapy, and in particular, as immunomodulators for cancer vaccines.

AB - Tumor-associated antigens (TAAs) are by definition either weakly immunogenic or functionally nonimmunogenic. Therefore, efforts have concentrated on the development of vaccine strategies in which the presentation of TAAs to the immune system results in far greater activation of T cells than that occurring naturally in the host. Several strategies are being explored in our laboratory and others to enhance the immunogenicity of TAAs. These are: (a) placing the gene coding for the tumor antigen, as a transgene, into poxvirus vectors. (b) The use of diversified prime and boost vaccine strategies employing two different types of poxvirus vectors. (c) The use of T-cell costimulation; accomplished by placing transgenes for different T-cell costimulation molecules into viral vectors along with the transgenes for the TAA. (d) Altering the amino acid sequence of the TAA to enhance the host immune response. (e) The use of cytokines, and in particular GM-CSF, as a biologic adjuvant. This review will focus on the current state of the use of costimulatory molecules as adjuvants for immunotherapy, and in particular, as immunomodulators for cancer vaccines.

KW - B7-1

KW - Costimulation

KW - Fowlpox

KW - ICAM-1

KW - Immunotherapy

KW - LFA-3

KW - Review

KW - Therapeutics

KW - Treatment

KW - TRICOM

KW - Vaccinia

UR - http://www.scopus.com/inward/record.url?scp=32944472992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32944472992&partnerID=8YFLogxK

U2 - 10.2741/1837

DO - 10.2741/1837

M3 - Article

VL - 11

SP - 788

EP - 803

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

IS - 1 P.447-888

ER -